Allergan plc (NYSE: AGN) Investor Securities Class Action Lawsuit 12/21/2018

If you purchased shares of Allergan plc (NYSE: AGN), you have certain options and for certain investors are short and strict deadlines running. Deadline: February 19, 2019. NYSE: AGN investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to, or call us at (858) 779-1554.
Company Name(s): 
Case Name: 
Allergan Shareholder Class Action Lawsuit 12/21/2018
Case Status: 
Lawsuit Filed
Affected Securities
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
Class Period Begin: 
Class Period End: 
Court of Filing: 
U.S. District Court for the Southern District of New York
Deadline To File for Lead: 

An investor in shares of Allergan plc (NYSE: AGN) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Allergan plc in connection with certain allegedly false and misleading statements made between May 9, 2017, and December 19, 2018.

Dublin, Ireland based Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. Allergan plc reported that its annual Total Revenue rose from over $14.57 billion in 2016 to over $15.94 billion in 2017 and that its Net Income of over $14.97 billion in 2016 declined to a Net Loss of over $41.2 billion in 2017.

On December 18, 2018, France's National Agency for the Safety of Medicines & Health Products ordered the recall of textured breast implants manufactured by Allergan plc from the European market, stating that the implants "have been linked to a rare form of cancer"—specifically, anaplastic large cell lymphoma. On December 19, 2018, Allergan plc stated that it would remove its textured breast implants from the European market.

Shares of Allergan plc (NYSE: AGN) declined to as low as $125.84 per share on December 26, 2018.
According to the complaint the plaintiff alleges on behalf of purchasers of Allergan plc (NYSE: AGN) common shares between May 9, 2017, and December 19, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 9, 2017, and December 19, 2018, the Allergan concealed from investors the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.